Pralsetinib FDA：This label may not be the latest approved by FDA. For current ...

This label may not be the latest approved by FDA. For current ...

Seefullprescribinginformationfor.GAVRETO.GAVRETO®(pralsetinib)capsules,fororaluse.InitialU.S.Approval:2020.--------- ...。其他文章還包含有：「FDAapprovespralsetinibfornon」、「FDAApprovalSummary」、「Gavreto(pralsetinib)FDAApprovalHistory」、「PralsetinibfortheTreatmentofLungandThyroidCancers...」、「BlueprintMedicinesAnnouncesFDAApprovalof...」、「FDAGrantsRegularApprovaltoPralsetinibforMetas...

查看更多離開網站

Provide From Google

FDA approves pralsetinib for non

https://www.fda.gov

Pralsetinib was previously granted accelerated approval for the NSCLC indication on Sept. 4, 2020, based on initial overall response rate (ORR) ...

Provide From Google

FDA Approval Summary

https://aacrjournals.org

The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non–small cell lung cancer (NSCLC) and December 1, 2020 for thyroid cancer, ...

Provide From Google

Gavreto (pralsetinib) FDA Approval History

https://www.drugs.com

FDA approval history for Gavreto (pralsetinib) used to treat Non Small Cell Lung Cancer, Thyroid Cancer. Supplied by Genentech, Inc.

Provide From Google

Pralsetinib for the Treatment of Lung and Thyroid Cancers ...

https://pubmed.ncbi.nlm.nih.go

The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non-small cell lung cancer (NSCLC) and December 1, 2020 for ...

Provide From Google

Blueprint Medicines Announces FDA Approval of ...

https://ir.blueprintmedicines.

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer.

Provide From Google